Walder Wyss advised Engimmune Therapeutics on the deal. Vischer advised the investors Pureos Bio-ventures and Novo Holdings.Engimmune Therapeutics completed a CHF 15.5m seed financing round co-led by…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
